The Business Research Company’s report on the Biopharmaceuticals Contract Manufacturing Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the key drivers behind the biopharmaceuticals contract manufacturing market’s growth in recent years?
The growing demand for personalized medicine is expected to propel the growth of the biopharmaceutical contract manufacturing market going forward. Personalized medicine refers to a customized healthcare approach that takes into account individual patient traits, including genetics, environment, and lifestyle, to enhance treatment effectiveness and outcomes. The increasing demand for personalized medicine is driven by several factors, including advancements in genomics, patient empowerment, and improved treatment efficacy. Contract manufacturers can create tailored production processes designed to fulfill the specific requirements of personalized therapies, accommodating small batch sizes and unique formulations. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Therefore, the growing demand for personalized medicine drives the growth of biopharmaceutical contract manufacturing market.
Access Your Free Sample of the Global Biopharmaceuticals Contract Manufacturing Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=10181&type=smp
How does the future projection of the biopharmaceuticals contract manufacturing market size compare to its historical growth?
The biopharmaceuticals contract manufacturing market size has grown rapidly in recent years. It will grow from$20.13 billion in 2024 to $22.21 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to increased biopharmaceutical development, cost efficiency and risk mitigation, growing pipeline of biologics, globalization of biopharmaceutical industry, flexible manufacturing solutions
The biopharmaceuticals contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to “$33.75 billion in 2029 at a compound annual growth rate (CAGR) of 11.0%. The growth in the forecast period can be attributed to increasing outsourcing trends, biosimilar development, shorter time-to-market requirements, global market expansion, focus on specialized services. Major trends in the forecast period include technological integration, outsourcing expansion beyond large molecules, advanced manufacturing technologies adoption, focus on quality and compliance, rise of biosimilars manufacturing, .
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=10181&type=smp
Which key players are shaping the future of the biopharmaceuticals contract manufacturing market?
Major companies operating in the biopharmaceuticals contract manufacturing market include Boehringer Ingelheim GmbH, Lonza Group Ltd., Inno Biologics Sdn Bhd, Rentschler Biopharma SE, Samsung Biologics Co. Ltd., AGC Biologics, ProBioGen AG, FUJIFILM Diosynth Biotechnologies, Thermo Fisher Scientific Inc., Binex Co. Ltd., AbbVie Inc., Catalent Inc, Pfizer Inc., Merck KGaA, Pressure BioSciences, Novartis International AG, Cambrex Corporation, Emergent BioSolutions Inc., JRS Pharma GmbH & Co. KG, WuXi Biologics, Siegfried Holding AG, Toyobo Co. Ltd., ADMA Biologics Inc., UCB S.A., AstraZeneca PLC, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Shire Pharmaceuticals LLC, Baxter International Inc., Becton Dickinson and Company, Polyphor Ltd., Patheon Inc., Alcami Corporation
What trends will propel the growth and evolution of the biopharmaceuticals contract manufacturing market?
Product innovations are a key trend gaining popularity in the biopharmaceuticals contract manufacturing market. Major companies operating in the biopharmaceutical contract manufacturing market are developing innovative products to sustain their position in the market. For instance, in February 2023, Thermo Fisher Scientific, a US-based biotechnology research company, and Elektrofi, a US-based biotechnology company specializing in drug formulation and delivery innovations, entered into a strategic contract manufacturing agreement to support the commercial production of Elektrofi’s ground-breaking ultra-high concentration subcutaneous products. Elektrofi’s proprietary microparticle technology enables small-volume injections of biologics such as monoclonal antibodies, therapeutic proteins, and other large-molecule medications important for human health. Elektrofi’s platform technology allows patients to self-inject medicines at home rather than in a hospital setting, overcoming the difficulties of administering biologic-based medications.
Which regions are expected to become dominant players in the biopharmaceuticals contract manufacturing market?
North America was the largest region in the biopharmaceutical contract manufacturing market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global biopharmaceuticals contract manufacturing market forecast period. The regions covered in the biopharmaceuticals contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Order Your Report Now For Swift Delivery
What are the emerging key segments in the biopharmaceuticals contract manufacturing market, and how are they evolving?
The biopharmaceuticals contract manufacturing market covered in this report is segmented –
1) By Product: Biologics, Monoclonal Antibodies (MABs), Recombinant Proteins, Vaccines, Antisense, RNAi, And Molecular Therapy, Biosimilars
2) By Source: Mammalian, Non-mammalian
3) By Service: Process Development, Fill And Finish Operations, Analytical And QC studies, Packaging
4) By Application: Clinical, Commercial
Subsegments:
1) By Biologics: Enzymes, Hormones, Antibodies
2) By Monoclonal Antibodies (MABs): Human MABs, Chimeric MABs, Murine MABs
3) By Recombinant Proteins: Insulin, Growth Factors, Cytokines
4) By Vaccines: Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines
5) By Antisense, RNAi, And Molecular Therapy: Antisense Oligonucleotides, RNA Interference Products, Gene Therapies
6) By Biosimilars: Biosimilar Monoclonal Antibodies, Biosimilar Insulin, Biosimilar Growth Hormones
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10181
What defines the structure and scope of the biopharmaceuticals contract manufacturing market?
Biopharmaceutical contract manufacturing refers to a process in which a biopharmaceutical company hires a third-party manufacturer to produce its drugs or biologic products on its behalf. It is utilized when pharmaceutical businesses employ the facilities of other companies to manufacture pharmaceuticals under their own brand. It is identical to private label or third-party production.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
